Colon cancer, commonly referred to as colorectal cancer, is known for being very sneaky. With little to no symptoms displayed in the early stages, patients are left with no forewarning. As the third most common type of cancer, this disease claims thousands of lives each year. With those numbers, organizations like the American Cancer Society, recommend colorectal cancer screenings begin at age 50. These screening tests can allow doctors to catch the disease early and hopefully at a curable stage, thus regular screenings are imperative.
In this Patient Power program, Dr. William Grady, associate professor of Medicine and Section Chief of the Division of Gastreanology at the Seattle Cancer Care Alliance, joins Andrew to discuss the latest in screening for colon cancer and current clinical trials. Find out about new techniques like virtual colonoscopy, learn how early detection is allowing some patients make a full recovery and why advanced colon cancer patients can be optimistic as well.
You'll hear Dr. Grady discuss the latest in screening methods for colon cancer including the fecal occult blood test and the flexible sigmoidoscopy test. Dr. Grady also touches on why the colonoscopy still remains one of the most trusted methods of testing. Listen to all this and more in this webcast sponsored by the Seattle Cancer Care Alliance. In Dr. Grady’s own words, “the most common sign of colon cancer is no symptom at all, and that's why screening is so important. But if symptoms do develop, it's usually a sign that a cancer is there, and it may be slightly more advanced, but still doing something about it sooner rather than later is the right strategy because that gives the best chance to cure it.” If you have been curious about colon cancer screening, don't wait, be proactive.
William Grady, M.D.
Gastroenterology Specialist, Seattle Cancer Care AllianceDr. Grady specializes in gastroenterology and internal medicine at the University of Washington School of Medicine. His particular clinical interests include diagnosis and treatment of hereditary cancer syndromes, as well as molucular markers for colon, liver, esophageal and stomach cancer. Dr. Grady received his medical degree from the University of Michigan Medical Center and was Internal Medicine Chief Resident at... more >